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Supplementary Table 1 - Clinical features of the five LMS patients included in this study and overall frequency of features in all 10 known typical cases 
(literature review). 
Features Pat. 1 Pat. 2 Pat. 3 Pat. 4 Pat. 5 Known cases 
(n=10) 
Previous report - reference New  
patient 
Saraiva 2000
1
 Wattanasirichai-
goon et al. 2004
2
 
Chrzanowska  
et al. 1989
3
 
New  
patient 
Pat. 1 + Pat. 5 + 
previous reports
1–10
 
Mutation PTDSS1 c.805C>T 
p.Pro269Ser 
c.1058A>G 
p.Gln353Arg 
c.1058A>G 
p.Gln353Arg 
c.1058A>G 
p.Gln353Arg 
c.794T>C 
p.Leu265Pro 
5/5 
Confirmed de novo +/+ ?/? +/+ +/+ +/+   4/4 
Sex Male Female Female Male Female M=6; F=4 
Origin Kurd-Turkish Portuguese Thai-Chinese Polish Czech  
Consanguinity - - - - - 0/10 
Father’s age at patient’s birth 37 33 35 25 30 34.9 (a) 
Mother’s age at patient’s birth 35 34 31 25 27  
Birth - gestational age (weeks) 38 37 38 41 39  
Length, cm (SD) ? 45 (-1.3) 46 (-1.3) 52 (-1.4) 44 (-4) 3/7 (b) 
Weight , g (SD) 2740 (-0.7) 3470 (+1.3) 2100 (<-2) 2550 (-2.5) 2700 (-1.3)  
Head circumference, cm (SD) ? 33 (0) 30 (<-2) 35 (+0.1) 32 (-2.2)  
Post natal growth - age, yrs 2 18 11.5 36 9  
Height, cm (SD) 72.3 (-4) 135 (-4,8) 98 (-7) 128.6 (-7.8) 84 (-10) 10/10 (b) 
Weight , kg (SD) 8.2  (-3) 39,5 (-2.9) 17 (-3) 34 (-3.5) 10 (-5)  
Head circumference, cm (SD) 43.3 (-4) 52,5 (-1.6) 50.5 (-2) 53 (-2.7) 44.2(-5)  
Intellectual disability 
Speech impairment 
Mod-Severe 
? 
Mild-Moderate 
+ (sentences) 
Severe 
+++ (absent) 
Borderline 
- (good) 
Severe 
++ (2 words) 
10/10 
Craniofacial features       
Delayed closure of fontanelles + + + ? + 9/9 
Broad/prominent forehead + + + + + 10/10 
Hypertelorism + + + + + 10/10 
Large ears + + + + + 10/10 
Choanal atresia + + ? - - 7/9 
Obstructed nasolacrimal ducts - + + + - 7/9 
Dental enamel hypoplasia ? +
 
(c) + + (c) + (c) 8/8 
Macroglossia/protruded tongue + + + - - 4/8 
Macrostomia + + + + + 10/10 
Prognathism + + + + + 7/8 
Sparse hair ? + + + + 5/6 
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Features Pat. 1 Pat. 2 Pat. 3 Pat. 4 Pat. 5 Known cases 
(n=10) 
Loose atrophic skin / cutis laxa + + + + + 10/10 
Prominent cutaneous veins + + + + + 10/10 
Joint laxity + + + + + 10/10 
Distal limbs       
Brachydactyly, more severe post-axially + + + + + 10/10 
Proximal symphalangism + + + + + 10/10 
Cutaneous syndactyly + + + + + 10/10 
Radiological features       
Skull and vertebra progressive sclerosis + + + + + 10/10 
Progressive diaphyseal hyperostosis + + -
 
(d) + + 8/9 
Diaphyseal undermodeling + + -
  
(d) + + 8/9 
Meta/epiphyseal radiolucency + ? -
  
(d) ? + 6/7 
Broad clavicles and ribs + + + + + 9/9 
Short/absent  middle phalanges + + + + + 10/10 
Phalangeal synostosis  + + + + + 10/10 
Metacarpal synostosis - - - -  - 1/10 
Humero-radial synostosis - - - + - 1/10 
Hemivertebra  + spina bifida oculta - - - + - 1/10 
Abnormal/delayed skeletal maturation + + + ? + 9/9 
Brain imaging  CT nl at 15m  MRI CT,MRI,MRV NP   
Diffuse cortical atrophy  - +  + 2/3 
Hydrocephalus/ enlarged ventricles  - +  + 3/6 
Pituitary hypoplasia  - +  + 2/3 
Leucoencephalopathy  + +  - 2/3 
Small central spinal canal    - +  - 1/3 
Vascular anomalies  - + (e)  - 1/3 
Dysgenesis of the corpus callosum  + -  - 1/3 
Others       
Cranial nerve palsy - - + - - 1/10 
Cleft palate - - + - - 1/10 
Hearing loss ? + - + - 2/4 
Ophthalmological problems - Small iris Entropion  Hypermetropia -  
Inguinal Hernia +  +  - - - 6/10 
Hypospadias and/or chordee - NA NA - NA 2/5 
Cryptorchidism + NA NA + NA 6/6 
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(a) Mean father’s age at birth (yrs) (for 8 of the 10 known patients); (b) patients’ length/height <-2SD); (c) all teeth were 
removed; (d) tubular bones in Pat. 3 show diffuse cortical hyperostosis instead of progressive diaphyseal hyperostosis and 
metaphyseal radiolucency as typically seen in other LMS patients; (e) persistent fetal origin of the right hypoglossal artery 
connecting with cervical right internal carotid artery; hypoplasia of straight sinus and accessory falcine sinus; CT – 
computed tomography; MRI – magnetic resonance imaging; MRV – magnetic resonance venography; + present, - absent; nl 
– normal. NP – not performed; NA – not applicable. 
 
Remarks on Supplementary Table 1 
The father’s age at patient’s birth was previously suggested to be advanced in LMS patients4 
but this was neither evident in our five cases nor globally in the 10 known cases. The overall mean 
age was 34.9 yrs; the mean paternal age in the general population is 27; the frequently used 
criterion for advanced paternal age is >40 yrs11.  
LMS is a progressive condition. With age, bone thickness increases, the radiological 
characteristics become more severe and the dysmorphic features more evident. The brachydactyly is 
also progressive, especially at the 4th and 5th rays, with sometimes development of phalangeal and 
metacarpal synostoses. The height of younger children (aged 3-5 yrs), was approximately -4SD and 
usually progressed to -7 to -8SD in adulthood. The loose skin might improve with time.  
In the five patients in this study, we did not observe significant genotype-phenotype 
correlations (Fig. 1 and Supplementary Table 1). Pat. 1 and Pat. 5 have the mutations p.Pro269Ser 
and p.Leu265Pro respectively. The zebrafish studies (Fig. 5) suggest that these mutations produce a 
more severe effect than the p.Gln353Arg mutation. The metabolic studies (Fig. 3-4) do not totally 
support this and clinically, however, it does not appear that Pat. 1 and 5 exhibit a more severe 
phenotype than Pat. 2, 3 and 4 whom have the p.Gln353Arg mutation. Pat. 2, 3 and 4 share this 
mutation but also show clear phenotypic differences. For example, Pat. 2 is taller but more severely 
affected at the craniofacial and intellectual levels than Pat. 4. Pat. 3 has severe intellectual disability 
as well as cleft palate, cranial nerve palsy and hydrocephalus (not observed in any of the other 
patients) and his long bones radiological features are somewhat unusual. It is possible that variants 
in other genes account for this variability.  
Besides the 10 known typical LMS patients (8 previously described1–10 and two patients 
reported here for the first time), two additional Japanese patients were described with milder 
phenotypes that overlap considerably with LMS and were proposed to have LMS-like or atypical 
forms of LMS12,13. We think there are significant differences between these two cases and the typical 
LMS phenotype and we did not include them in the present table. Nevertheless, they might share 
common pathogenic mechanisms with LMS, being important to screen PTDSS1 (and eventually other 
genes involved in phosphatidylserine metabolism) in these patients as well as in other conditions 
that overlap with LMS, particularly other craniotubular dysplasias without known genetic etiology.   
Nature Genetics: doi:10.1038/ng.2829
Supplementary Table 2 - Overview of exome sequencing output.  
Sample Yield 
(kBases) 
Reads Mapped 
reads 
Paired 
Mapped 
reads 
Mean 
coverage 
% target 
bases 
at >=15X 
% target 
bases 
at >=30X 
Pat. 1 9221256 91299584 89669573 87829536 95 89.2 81.1 
Father 1 8504384 84201824 82864993 80540344 91 88.9 80.7 
Mother 1 8816388 87290972 85753417 83748298 91 88.9 80.9 
Pat. 2 8037534 79579552 78277445 76436884 86 88.1 79.4 
Pat. 3 8087420 80073476 78231116 75058196 85 88.3 79.5 
Pat. 4 7695114 76189260 73960824 67883606 82 87.0 77.4 
Father 4 9309552 92173786 89434661 84572100 104 89.1 81.9 
Mother 4 9343872 92513596 90221305 86098854 109 90.2 83.8 
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Supplementary Table 3 – Filtering of variants identified by whole-exome sequencing. 
Filtering parameters Variant filtering 
Pat. 1 Pat. 2 Pat. 3 Pat. 4 
Exonic and splice variantsa 19,488 19,136 18,970 18,344 
Heterozygous 11,631 11,431 10,580 10,676 
Nonsense, splice or missense variants 5,618 5,580 5,229 5,151 
Novel or rareb 406 391 449 274 
De novo (trio analysis) 35 NA NA 26 
Predicted damagingc 19 195 233 13 
 Nº of genes with variants in at least x affected individuals 
 x=2 x=3 x=4 
Post above filtering   11 4 1 
 
a Included SNV and indels on exons and splice sites (as defined by Ensembl/Polyphen14: “a sequence variant in 
which a change has occurred within the region of the splice site, either within 1-3 bases of the exon or 3-8 
bases of the intron”) 
b Included variants that were not present in our internal database containing 80 exomes of phenotypically-
characterized individuals processed similarly, and not present in more than 0.5% of the NCBI dbSNP build 13215 
and the 1000Genome16 databases. 
c Included nonsense, essential splice-site (as defined by Ensembl/Polyphen14: a splice variant that changes the 
2 base region at the 5’ end or 3’ end of an intron) and missense variants predicted damaging by sift17 and/or 
polyphen14 
NA – not applicable 
 
Remarks on Supplementary Table 3  
The filtering and variant prioritization approach summarized in this table combined data from whole 
exome-sequencing of both the mother-father-child trios (Pat. 1 and Pat. 4) and the two affected 
patients (Pat. 2 and Pat. 3) for whom parental DNA samples were unavailable at the time. 
Considering a de novo mode of inheritance within each trio, potentially pathogenic variants were 
identified in 19 genes for Pat. 1 and 13 genes for Pat. 4. Only 2 genes were common to both affected 
patients: PTDSS1 and MUC17. The variant identified in MUC17 in Pat. 4 was paternally inherited but 
was excluded at the sequence calling level due to insufficient quality and coverage. The analysis of 
both trios would be sufficient to indicate PTDSS1 as a single candidate gene. 
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Supplementary Table 4 – Pathogenicity prediction of the de novo missense PTDSS1 mutations identified in LMS patients using the following in silico tools: 
Polyphen-214, PROVEAN18, SIFT17 and MutPred19. Each mutation was predicted to be deleterious by all programs used. 
 
Position 
Mutation  
PTDSS1 
Polyphen-214 PROVEAN18 SIFT17 
MutPred19 
Probability 
of 
deleterious 
mutation 
Molecular Mechanism Disrupted 
- Top 5 features (P values) 
8:97316309 
c.T794C 
p.L265P 
Probably 
Damaging 
(1.000) 
Deleterious 
(-6.542) 
Damaging 
(0.001) 
0.789 
Loss of sheet (P = 0.007) 
Gain of loop (P = 0.024) 
Gain of disorder (P = 0.0251) 
Loss of MoRF binding (P = 0.0579) 
Gain of methylation at K261 (P = 0.0637) 
8:97316320 
c.C805T 
p.P269S 
Probably 
Damaging 
(1.000) 
Deleterious 
(-7.933) 
Damaging 
(0.001) 
0.936 
Gain of MoRF binding (P = 0.0336) 
Gain of relative solvent accessibility (P = 0.09) 
Gain of catalytic residue at P269 (P = 0.1756) 
Gain of solvent accessibility (P = 0.1846) 
Gain of sheet (P = 0.1945) 
8:97321835 
c.A1058G 
p. Q353R 
Probably 
Damaging 
(0.999) 
Deleterious 
(-3.488) 
Damaging 
(0.000) 
0.828 
Gain of sheet (P = 0.039) 
Loss of ubiquitination at K348 (P = 0.0397) 
Gain of MoRF binding (P = 0.0534) 
Gain of relative solvent accessibility (P = 0.1259) 
Gain of solvent accessibility (P = 0.1319) 
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Supplementary Figure 1 - Sanger sequencing chromatograms showing the PTDSS1 heterozygous 
mutations identified in this study. Patients 2, 3 and 4 share the same missense mutation c.A1058G 
(p.Gln353Ag) in exon 9. Patients 1 and 5 have point mutations c.C805T (p.Pro269Ser) and c.T794C 
(p.Leu265Pro), respectively, which are located in exon 7. Position of each mutation is indicated by a 
red arrow. Sequence analysis of the parents of patients 1, 3, 4 and 5 confirmed these mutations are 
de novo (data not shown). 
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Supplementary Figure 2 - Clustal W220 alignment of the human PSS1 protein and its orthologues in 
selected species shows a very high degree of conservation. The amino acids residues at each of the 
identified mutations (Leu265Pro, Pro269Ser and Gln353Ag) are highlighted by grey shaded boxes 
and are completely conserved. 
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Supplementary Figure 3  – Specificity of end-product inhibition of phosphatidylserine (PS) synthesis. 
Control (Ctrl A) and Pat. 4 (Q353R) fibroblasts were seeded at 1.5x105 cells/60-mm dishes. After 3 
days, cells were incubated in fresh growth medium at 37°C for 2 h in the absence (no add) or 
presence of phosphatidylcholine (PC) liposomes (80 μM) or PS liposomes (80 μM), then incubated 
with [3H]serine for 3 h ± PC or PS liposomes. Phospholipids were extracted21, separated by thin-layer 
chromatography and radioactivity was measured in PS and PS-derived phosphatidylethanolamine 
(PE). Note exogenously added PC did not reduce the incorporation of [3H]serine into PS (a) or PS-
derived PE (b) in either Ctrl or LMS fibroblasts. Data are means ± S.D. from triplicate analyses of one 
of two independent experiments with similar results. 
 
  
a 
b 
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Supplementary Figure 4 - Resistance of serine-exchange activity to inhibition by phosphatidylserine 
(PS, concentrations 0 to 200 µM) in skin fibroblasts from control (Ctrl) and LMS patients. Serine-
exchange activity (PSS1 + PSS2) was measured in the absence (no PS; white bars) and presence of 
indicated amounts of PS liposomes (grey bars; 50, 100, or 200 μM PS). In contrast to control cells, in 
LMS fibroblasts serine-exchange activity was resistant to inhibition by PS, even at the lowest dose 
used. 
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Supplementary Figure 5 – TUNEL staining of zebrafish embryos at 25 hours post-fertilization injected 
with the highest 500 pg dose of wild-type (WT) or mutant (p.P269S) RNA. Two experiments were 
performed with >30 injected embryos analyzed in each of them. No difference in apoptosis is 
observed.  
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Supplementary Figure 6 – Anti-phosphohistone H3 staining of zebrafish embryos at 25 hours post-
fertilisation injected with the highest 500 pg dose of wild-type (WT) or mutant (p.P269S) RNA 
compared to an uninjected control. Two experiments were performed with >30 injected embryos 
analyzed in each of them. No overt difference in cell proliferation (H3+ve cells) was observed. 
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Supplementary Figure 7 – Reverse Transcription Quantitative PCR (RT-qPCR) mRNA analysis of (a) 
PTDSS1 and (b) PTDSS2 genes in selected tissues from first and second trimester normal human 
fetuses. mRNA levels for PTDSS1 and PTDSS2 are quantified relative to the level of glyceraldehyde-3-
phosphate dehydrogenase  (GAPDH) mRNA. Data are means ± SEM. N - number of fetuses analyzed 
for each type of tissue. (c,d) Individual results for brain and skin tissues from different fetuses. Note 
that both brain and skin showed an increasing expression of PTDSS1 and PTDSS2 with gestational 
age during the second trimester of pregnancy. 
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Supplementary Figure 8 - Regional distribution of (a) PTDSS1 and (b) PTDSS2 expression in human 
brain. Box plots of mRNA levels from 10 brain regions are based on microarray experiments and 
plotted on a log2 scale (y-axis). Variation in PTDSS1 and PTDSS2 transcript expression is shown 
across 10 brain regions, from left to right: the cerebellum (CRBL, n=130), frontal cortex (FCTX, 
n=127), hippocampus (HIPP, n=122), medulla (specifically inferior olivary nucleus, MEDU, n=119), 
occipital cortex (specifically primary visual cortex, OCTX, n=129), putamen (PUTM, n=129), 
substantia nigra (SNIG, n=101), temporal cortex (TCTX, n=119), thalamus (THAL, n=124), and 
intralobular white matter (WHMT, n=131). Material and methods were as previously reported22,23. In 
brief, these samples originate from 134 adult individuals from the UK Brain Expression Consortium 
and were profiled on 1231 Affymetrix Human Exon 1.0 ST arrays. Whiskers extend from the box to 
1.5 times the inter-quartile range. (c-f) Spatio-temporal PTDSS1 and PTDSS2 transcriptome of the 
human brain using data from the Human Brain Transcriptome (HBT) database24. This study assessed 
16 brain regions of the brain over 15 periods of the human pre and post-natal development. These 
data were generated from Affymetrix Human Exon 1.0 ST Arrays performed on 1,340 tissue samples 
collected from 57 developing and adult post-mortem brains of clinically unremarkable donors 
representing males and females of multiple ethnicities. (c,d) Spatio-temporal expression of PTDSS1 
and PTDSS2 mRNA on a log2 scale in 6 brain regions: the cerebellar cortex (CBC), mediodorsal 
nucleus of the thalamus (MD), striatum (STR), amygdale (AMY), hippocampus (HIP) and the 
neocortex (NCX). (e,f) Spatio-temporal expression of PTDSS1 and PTDSS2 mRNA in 11 regions of the 
neocortex: 5 at the frontal cortex (OFC, DFC, VFC, MFC, M1C), 2 at the parietal cortex (S1C, IPC), 3 at 
the temporal cortex (A1C, STC, ITC) and 1 at the occipital cortex (V1C).  
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Remarks on Supplementary Figure 8 
In these two large sets of data, it is evident the high brain PTDSS1 and relatively less PTDSS2 
expression. It corresponds to both mouse data and strongly supports our RT-qPCR data from human 
fetal brain samples (Supplementary Fig. 6). The PTDSS1 expression in the white matter is 
considerably lower than other regions and relative to the PTDSS2 profile (a,b), while the cerebellum 
is slightly lower in both array studies (a,c). All regions of the neocortex (e) show similar high PTDSS1 
expression and some LMS patients do show some degree of cortical brain atrophy. The temporal 
pattern of PTDSS1 expression seems consistent in all regions of the brain (c) and within the distinct 
areas of the neocortex (e). PTDSS1 brain expression is significantly higher prenatally showing an 
evident increase in the first and second trimesters (c,e), (corroborating our RT-qPCR results in 
Supplementary Fig. 6), with subsequent decrease in the third trimester but then maintaining high 
expression throughout childhood and adult life. 
  
Nature Genetics: doi:10.1038/ng.2829
Supplementary Figure 9 – Analysis of skin biopsy and cultured fibroblasts using electron microscopy. 
(a) Skin biopsy dermis of Pat. 4 showing two fibroblasts with numerous cytoplasmic vacuoles. There 
is a paucity of elastic tissue in the surrounding area (original magnification x1200). (b) High power 
view of the tail of a fibroblast from Pat. 4 skin biopsy with membrane bound vacuoles containing 
granular material suggestive of a degradative or phagocytic process (original magnification x5000). 
(c) Normal skin with fibroblast and grey bands of elastic fibers (arrow), for comparison (original 
magnification x2000). (d) Low power electron micrograph showing a cultured fibroblast from Pat. 1. 
Note the displaced nucleus and numerous vacuoles with mainly electron dense material (original 
magnification x1,200). (e) High power image of the same cell with membrane bound vacuoles and 
stored material. The density and morphology of the material is suggestive of having a lipid 
component (original magnification x4000). Similar findings were observed in cultured fibroblasts 
from Pat. 4. (f) Control cultured fibroblast for comparison. Low power image of control sample 
showing a solitary fibroblast with empty cytoplasmic vacuoles (original magnification x 1200). (g) 
High power image of the same cell with a few mitochondria, rough endoplasmic reticulum and no 
stored material in the vacuoles (original magnification x4000). 
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Remarks on Supplementary Figure 9 
Electron microscopy studies of peripheral blood leucocytes in two of our patients did not reveal any 
consistent abnormality. Infrequent lymphocytes appear to contain small membrane bound 
cytoplasmic vacuoles with no specific identifiable material. 
We have specifically looked for signs of apoptosis in all the electron microscopy images of skin from 
Pat. 4, blood lymphocytes and fibroblast cultures from Pat. 1 and Pat. 4 LMS patients. We could not  
find convincing evidence of true apoptosis in any of the samples.  
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Supplementary Figure 10 - Staining of neutral lipids and quantification of cellular triacylglycerol 
content in skin fibroblasts. (a) BODIPY staining of neutral lipids in skin fibroblasts from control (Ctrl 
B) and two LMS patients (Pat. 1, P269S and Pat. 4, Q353R). Two representative confocal images 
(objectif 60X) per cell line are shown. Neutral lipids were stained with BODIPY 493/503, nuclei were 
stained with DAPI (blue). Scale bar, 20 μm. Lipid droplets (containing stored neutral lipids, such as 
triacylglycerols and cholesteryl esters) show punctate BODIPY staining, while the diffuse green 
staining is likely displayed by reticulate structures of the cell. (b) average BODIPY intensity in 
arbitrary fluorescence units (AFU) from 5 random fields/cell line, containing >15 cells each (c) 
Cellular triacylglycerol (TAG) content of skin fibroblasts from control (Ctrl B) and two LMS patients 
(P269S and Q353R). Data are means ± S.D. of triplicate analyses. 
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Supplementary Figure 11 – Quantitative analysis of “apoptosis” rate (Annexin V positive / total cells) 
was applied to three controls and three LMS cell lines. Bars indicate means±SEM. A 6-fold increase in 
number of Annexin V positive cells was observed in LMS fibroblasts (*P<0,05). 
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